Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

Systematic Gene Overexpression in Candida albicans identifies a Regulator of Early Adaptation to the Mammalian Gut.

Znaidi S, van Wijlick L, Cervantes AH, Sertour N, Desseyn JL, Vincent F, Atanassova R, Gouyer V, Munro CA, Bachellier-Bassi S, Dalle F, Jouault T, Bougnoux ME, d'Enfert C.

Cell Microbiol. 2018 Jul 11:e12890. doi: 10.1111/cmi.12890. [Epub ahead of print]

PMID:
29998470
2.

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F.

Gastroenterol Res Pract. 2018 Jun 10;2018:2373868. doi: 10.1155/2018/2373868. eCollection 2018.

3.

Preclinical models for precision oncology.

Ibarrola-Villava M, Cervantes A, Bardelli A.

Biochim Biophys Acta. 2018 Jun 28. pii: S0304-419X(18)30066-0. doi: 10.1016/j.bbcan.2018.06.004. [Epub ahead of print] Review.

PMID:
29959990
4.

Borderline resectable pancreatic cancer. Challenges and controversies.

Sabater L, Muñoz E, Roselló S, Dorcaratto D, Garcés-Albir M, Huerta M, Roda D, Gómez-Mateo MC, Ferrández-Izquierdo A, Darder A, Cervantes A.

Cancer Treat Rev. 2018 Jun 13;68:124-135. doi: 10.1016/j.ctrv.2018.06.006. [Epub ahead of print] Review.

PMID:
29957372
5.

In the literature: June 2018.

Pérez-Fidalgo JA, Gambardella V, Cervantes A.

ESMO Open. 2018 Jun 20;3(4):e000401. doi: 10.1136/esmoopen-2018-000401. eCollection 2018. No abstract available.

6.

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?

Roda D, Ciardiello F, Cervantes A.

ESMO Open. 2018 Jun 20;3(4):e000392. doi: 10.1136/esmoopen-2018-000392. eCollection 2018. No abstract available.

7.

Abdominal obesity and insulin resistance after an episode of acute pancreatitis.

Singh RG, Pendharkar SA, Cervantes A, Cho J, Miranda-Soberanis V, Petrov MS.

Dig Liver Dis. 2018 May 1. pii: S1590-8658(18)30720-5. doi: 10.1016/j.dld.2018.04.023. [Epub ahead of print]

PMID:
29908753
8.

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?

Patel UB, Cervantes A, Fernández-Martos C, Sclafani F, Cunningham D, Nilsson P, Brown G.

Colorectal Dis. 2018 May;20 Suppl 1:56-60. doi: 10.1111/codi.14081.

PMID:
29878678
9.

Phase II Study of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards D, Krop I, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 May 23. pii: clincanres.0613.2018. doi: 10.1158/1078-0432.CCR-18-0613. [Epub ahead of print]

PMID:
29793946
10.

Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points.

Roselló S, Cervantes A.

Ann Oncol. 2018 Jul 1;29(7):1493-1494. doi: 10.1093/annonc/mdy182. No abstract available.

PMID:
29767693
11.

Role of epigenetic factors in the selection of the alternative splicing isoforms of human KRAS in colorectal cancer cell lines.

Riffo-Campos ÁL, Gimeno-Valiente F, Rodríguez FM, Cervantes A, López-Rodas G, Franco L, Castillo J.

Oncotarget. 2018 Apr 17;9(29):20578-20589. doi: 10.18632/oncotarget.25016. eCollection 2018 Apr 17.

12.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee.

Ann Oncol. 2018 May 5. doi: 10.1093/annonc/mdy158. [Epub ahead of print] No abstract available.

PMID:
29741578
13.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee.

Ann Oncol. 2018 May 5. doi: 10.1093/annonc/mdy161. [Epub ahead of print] No abstract available.

PMID:
29741565
14.

Correction: New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status.

Telechea-Fernández M, Rodríguez-Fernández L, García C, Zaragozá R, Viña JR, Cervantes A, García-Trevijano ER.

Oncotarget. 2018 Apr 6;9(26):18664. doi: 10.18632/oncotarget.25142. eCollection 2018 Apr 6.

15.

Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.

Peeters M, Cervantes A, Moreno Vera S, Taieb J.

Future Oncol. 2018 Jul;14(16):1629-1645. doi: 10.2217/fon-2018-0147. Epub 2018 Apr 27.

16.

System steganalysis with automatic fingerprint extraction.

Cervantes A, Sloan T, Hernandez-Castro J, Isasi P.

PLoS One. 2018 Apr 25;13(4):e0195737. doi: 10.1371/journal.pone.0195737. eCollection 2018. Erratum in: PLoS One. 2018 Jul 5;13(7):e0200457.

17.

In the literature: April 2018.

Gambardella V, Bruixola G, Cervantes A.

ESMO Open. 2018 Apr 13;3(3):e000362. doi: 10.1136/esmoopen-2018-000362. eCollection 2018. No abstract available.

18.

Confirmation and refinement of the heterozygous deletion of the small leucine-rich proteoglycans associated with posterior amorphous corneal dystrophy.

Cervantes AE, Gee KM, Whiting MF, Frausto RF, Aldave AJ.

Ophthalmic Genet. 2018 Aug;39(4):419-424. doi: 10.1080/13816810.2018.1459736. Epub 2018 Apr 19.

PMID:
29671669
19.

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Lee CR, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, Hamrick K, Polasek MJ, Lee JA, Clarke M, Cicci JD, Weck KE, Stouffer GA.

Circ Genom Precis Med. 2018 Apr;11(4):e002069. doi: 10.1161/CIRCGEN.117.002069.

PMID:
29615454
20.

Precision medicine in the adjuvant treatment of gastric cancer.

Gambardella V, Cervantes A.

Lancet Oncol. 2018 May;19(5):583-584. doi: 10.1016/S1470-2045(18)30131-1. Epub 2018 Mar 19. No abstract available.

PMID:
29567072
21.

Internet Use and Psychological Well-Being at Advanced Age: Evidence from the English Longitudinal Study of Aging.

Quintana D, Cervantes A, Sáez Y, Isasi P.

Int J Environ Res Public Health. 2018 Mar 9;15(3). pii: E480. doi: 10.3390/ijerph15030480.

22.

New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status.

Telechea-Fernández M, Rodríguez-Fernández L, García C, Zaragozá R, Viña J, Cervantes A, García-Trevijano ER.

Oncotarget. 2018 Jan 3;9(10):9100-9113. doi: 10.18632/oncotarget.23888. eCollection 2018 Feb 6. Erratum in: Oncotarget. 2018 Apr 6;9(26):18664.

23.

In the literature: February 2018.

Cervantes A.

ESMO Open. 2018 Feb 1;3(2):e000322. doi: 10.1136/esmoopen-2018-000322. eCollection 2018. No abstract available.

24.

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, André T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A.

Ann Oncol. 2018 May 1;29(5):1099-1107. doi: 10.1093/annonc/mdy064.

PMID:
29438451
25.

Genome Sequence of Hydrogenovibrio sp. Strain SC-1, a Chemolithoautotrophic Sulfur and Iron Oxidizer.

Neely C, Bou Khalil C, Cervantes A, Diaz R, Escobar A, Ho K, Hoefler S, Smith HH, Abuyen K, Savalia P, Nealson KH, Emerson D, Tully B, Barco RA, Amend J.

Genome Announc. 2018 Feb 1;6(5). pii: e01581-17. doi: 10.1128/genomeA.01581-17.

26.

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.

Roselló S, Papaccio F, Roda D, Tarazona N, Cervantes A.

Cancer Treat Rev. 2018 Feb;63:156-171. doi: 10.1016/j.ctrv.2018.01.001. Epub 2018 Jan 11. Review.

PMID:
29407455
27.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Jan 19. doi: 10.1007/s10637-018-0562-4. [Epub ahead of print]

PMID:
29349598
28.

Pro-inflammatory cytokines after an episode of acute pancreatitis: associations with fasting gut hormone profile.

Pendharkar SA, Singh RG, Chand SK, Cervantes A, Petrov MS.

Inflamm Res. 2018 Apr;67(4):339-350. doi: 10.1007/s00011-017-1125-4. Epub 2017 Dec 29.

PMID:
29288273
29.

mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival.

García-García AB, Gómez-Mateo MC, Hilario R, Rentero-Garrido P, Martínez-Domenech A, Gonzalez-Albert V, Cervantes A, Marín-Garcia P, Chaves FJ, Ferrández-Izquierdo A, Sabater L.

Oncotarget. 2017 Aug 3;8(62):104796-104805. doi: 10.18632/oncotarget.20076. eCollection 2017 Dec 1.

30.

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.

Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scotté F, Strasser F, Young A, Bruera E, Herrstedt J, Keefe D, Laird B, Walsh D, Douillard JY, Cervantes A.

Ann Oncol. 2018 Jan 1;29(1):36-43. doi: 10.1093/annonc/mdx757.

PMID:
29253069
31.

Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score.

Roselló S, Frasson M, García-Granero E, Roda D, Jordá E, Navarro S, Campos S, Esclápez P, García-Botello S, Flor B, Espí A, Masciocchi C, Valentini V, Cervantes A.

Clin Colorectal Cancer. 2018 Jun;17(2):104-112.e2. doi: 10.1016/j.clcc.2017.10.014. Epub 2017 Oct 28.

PMID:
29162332
32.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929
33.

Perfusion-based human cadaveric specimen as a simulation training model in repairing cerebrospinal fluid leaks during endoscopic endonasal skull base surgery.

Christian EA, Bakhsheshian J, Strickland BA, Fredrickson VL, Buchanan IA, Pham MH, Cervantes A, Minneti M, Wrobel BB, Giannotta S, Zada G.

J Neurosurg. 2017 Nov 3:1-5. doi: 10.3171/2017.5.JNS162982. [Epub ahead of print]

PMID:
29099299
34.

Elucidating the molecular basis of PPCD: Effects of decreased ZEB1 expression on corneal endothelial cell function.

Zakharevich M, Kattan JM, Chen JL, Lin BR, Cervantes AE, Chung DD, Frausto RF, Aldave AJ.

Mol Vis. 2017 Oct 14;23:740-752. eCollection 2017.

35.

Liquid biopsy: another tool towards tailored therapy in colorectal cancer.

Tarazona N, Cervantes A.

Ann Oncol. 2018 Jan 1;29(1):7-8. doi: 10.1093/annonc/mdx641. No abstract available.

PMID:
29045545
36.

Nance-Horan syndrome in females due to a balanced X;1 translocation that disrupts the NHS gene: Familial case report and review of the literature.

Gómez-Laguna L, Martínez-Herrera A, Reyes-de la Rosa ADP, García-Delgado C, Nieto-Martínez K, Fernández-Ramírez F, Valderrama-Atayupanqui TY, Morales-Jiménez AB, Villa-Morales J, Kofman S, Cervantes A, Morán-Barroso VF.

Ophthalmic Genet. 2018 Jan-Feb;39(1):56-62. doi: 10.1080/13816810.2017.1363245. Epub 2017 Sep 18. Review.

PMID:
28922055
37.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40. doi: 10.1093/annonc/mdx224. No abstract available.

PMID:
28881920
38.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv100-iv118. doi: 10.1093/annonc/mdx216. No abstract available.

PMID:
28881914
39.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

40.

In the literature: April 2017.

Cervantes A.

ESMO Open. 2017 May 2;2(2):e000193. doi: 10.1136/esmoopen-2017-000193. eCollection 2017. No abstract available.

41.

In the literature: February 2017.

Cervantes A, Terol MJ.

ESMO Open. 2017 Mar 24;2(1):e000171. doi: 10.1136/esmoopen-2017-000171. eCollection 2017. No abstract available.

42.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

PMID:
28600476
43.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.

Oncologist. 2017 Sep;22(9):1024-e89. doi: 10.1634/theoncologist.2017-0175. Epub 2017 Jun 7.

44.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

45.

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F.

Ann Oncol. 2017 Aug 1;28(8):1713-1729. doi: 10.1093/annonc/mdx175.

PMID:
28407110
46.

Meta-analysis of effects of inoculation with homofermentative and facultative heterofermentative lactic acid bacteria on silage fermentation, aerobic stability, and the performance of dairy cows.

Oliveira AS, Weinberg ZG, Ogunade IM, Cervantes AAP, Arriola KG, Jiang Y, Kim D, Li X, Gonçalves MCM, Vyas D, Adesogan AT.

J Dairy Sci. 2017 Jun;100(6):4587-4603. doi: 10.3168/jds.2016-11815. Epub 2017 Mar 23.

47.

Self-expanding metallic stent as a bridge to surgery in the treatment of left colon cancer obstruction: Cost-benefit analysis and oncologic results.

Flor-Lorente B, Báguena G, Frasson M, García-Granero A, Cervantes A, Sanchiz V, Peña A, Espí A, Esclapez P, García-Granero E.

Cir Esp. 2017 Mar;95(3):143-151. doi: 10.1016/j.ciresp.2016.12.014. Epub 2017 Mar 21. English, Spanish.

PMID:
28336185
48.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

49.

Vortex Pattern of Corneal Deposits in Granular Corneal Dystrophy Associated With the p.(Arg555Trp) Mutation in TGFBI.

Kattan JM, Serna-Ojeda JC, Sharma A, Kim EK, Ramirez-Miranda A, Cruz-Aguilar M, Cervantes AE, Frausto RF, Zenteno JC, Graue-Hernandez EO, Aldave AJ.

Cornea. 2017 Feb;36(2):210-216. doi: 10.1097/ICO.0000000000001045.

50.

Confirmation of the OVOL2 Promoter Mutation c.-307T>C in Posterior Polymorphous Corneal Dystrophy 1.

Chung DD, Frausto RF, Cervantes AE, Gee KM, Zakharevich M, Hanser EM, Stone EM, Heon E, Aldave AJ.

PLoS One. 2017 Jan 3;12(1):e0169215. doi: 10.1371/journal.pone.0169215. eCollection 2017.

Supplemental Content

Loading ...
Support Center